Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression
Braz. j. med. biol. res
;
38(11): 1609-1613, Nov. 2005. ilus
Article
in English
| LILACS
| ID: lil-414729
ABSTRACT
The biologic basis of the negative prognosis of plasmablastic myeloma is not fully understood. To determine whether histologically aggressive multiple myeloma (MM) is associated with a more angiogenic marrow environment, bone marrow samples from 50 recently diagnosed MM patients were evaluated. Twelve percent (6/50) of patients presented plasmablastic MM, and this feature correlated with moderate/strong intensity of vascular endothelial growth factor staining of plasma cells (P = 0.036). Although plasmablastic MM was not associated with increasing of microvessel density, this new evidence of increased expression of vascular endothelial growth factor on plasmablasts suggests that the adverse prognosis conferred by plasmablastic disease may be due, at least in part, to secretion of this angiogenic cytokine, also suggesting that the subset of MM patients with plasmablastic features may derive particular benefit from antiangiogenic therapies.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Bone Marrow
/
Vascular Endothelial Growth Factor A
/
Multiple Myeloma
/
Neovascularization, Pathologic
Type of study:
Prognostic study
/
Risk factors
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
English
Journal:
Braz. j. med. biol. res
Journal subject:
Biology
/
Medicine
Year:
2005
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Universidade Federal de São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS